Current Status
Not Enrolled
Get Started

After completion of this activity, the participant will:

  1. Be able to describe the symptoms of pediatric patients with MIS-C.
  2. Understand the similarities and differences between MIS-C and Kawasaki’s disease.
  3. Be familiar with the use of immunoglobulin for the treatment of Kawasaki disease and MIS-C, including typical dosing regimens.
  4. Be familiar with possible adjunctive treatments of Kawasaki Disease and MIS-C with immunomodulator medications including Anakinra and Tocilizumab.

Supported by an educational grant from: Kedrion Biopharma

Kenneth Paris, MD
Tamara Bradford, MD

Nursing 1 contact hour
ACPE 1 contact hour

1 IgCN® / IgCP® Recertification Units

This webinar was pre-recorded June 2020.